AU2022380491A1 - Novel auristatin analogs and immunoconjugates thereof - Google Patents

Novel auristatin analogs and immunoconjugates thereof Download PDF

Info

Publication number
AU2022380491A1
AU2022380491A1 AU2022380491A AU2022380491A AU2022380491A1 AU 2022380491 A1 AU2022380491 A1 AU 2022380491A1 AU 2022380491 A AU2022380491 A AU 2022380491A AU 2022380491 A AU2022380491 A AU 2022380491A AU 2022380491 A1 AU2022380491 A1 AU 2022380491A1
Authority
AU
Australia
Prior art keywords
compound
immunoconjugate
int
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022380491A
Other languages
English (en)
Inventor
Dong Jun Lee
Richard Hui LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adcentrx Therapeutics Inc
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of AU2022380491A1 publication Critical patent/AU2022380491A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022380491A 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof Pending AU2022380491A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
AU2022380491A1 true AU2022380491A1 (en) 2024-05-30

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022380491A Pending AU2022380491A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Country Status (9)

Country Link
EP (1) EP4426714A4 (https=)
JP (1) JP2024540402A (https=)
KR (1) KR20240110584A (https=)
AU (1) AU2022380491A1 (https=)
CA (1) CA3236944A1 (https=)
IL (1) IL312533A (https=)
MX (1) MX2024005342A (https=)
TW (1) TW202334176A (https=)
WO (1) WO2023081230A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
CA3236944A1 (en) 2023-05-11
EP4426714A1 (en) 2024-09-11
TW202334176A (zh) 2023-09-01
MX2024005342A (es) 2024-09-27
IL312533A (en) 2024-07-01
KR20240110584A (ko) 2024-07-15
WO2023081230A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
JP2024540402A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
CA2951368A1 (en) Auristatin derivatives and conjugates thereof
CN105451773A (zh) 细胞增殖抑制剂及其缀合物
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
TW202400266A (zh) 配體藥物偶聯物及其應用
EP4426714A1 (en) Novel auristatin analogs and immunoconjugates thereof
WO2023122228A1 (en) Novel auristatin analogs and immunoconjugates thereof
CN121574085A (zh) 缀合物及其用途
EP4471005A1 (en) Conjugate and use thereof
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40115429A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors
HK40117241A (zh) 新型澳瑞他汀类似物及其免疫偶联物
EP4633738A1 (en) Cytotoxic compounds
WO2024127333A1 (en) Cytotoxic compounds